Navigation Links
Trial Vaccine May Protect Against Serious Viral Infection
Date:3/18/2009

Women given injection could cut risk for CMV in half, study suggests

WEDNESDAY, March 18 (HealthDay News) -- Women who were given an experimental vaccine for a viral infection that can cause serious problems in babies, known as cytomegalovirus, reduced their risk of infection by 50 percent for as long as three and half years after vaccination, according to new research.

"In many ways, this was a surprising result," said the lead author of the study, Dr. Robert Pass, a professor of pediatrics at the University of Alabama at Birmingham. "Many people in the field felt it would be very difficult to prevent infection in mothers. We thought the best we could hope for was a vaccine for women that would prevent infection in a baby."

Results of the study are published in the March 19 issue of the New England Journal of Medicine.

Cytomegalovirus, or CMV, causes severe hearing, mental or movement impairments each year in about 8,000 infants who develop the infection while still in the womb, according to the National Institute of Allergy and Infectious Diseases.

The virus is very common and spreads easily, according to Pass. He said one reason researchers thought an effective vaccine would be so difficult to develop was that the virus adapts to attacks from the human immune system. And unlike infection from such viruses as chickenpox and measles, people can be re-infected with CMV many years after an initial infection.

Anyone can develop a CMV infection, and healthy adults and children usually don't show symptoms of the infection.

The new vaccine is made from a single CMV protein that was combined with an experimental adjuvant, a substance that's added to vaccines to boost their efficacy.

The study was a phase 2 trial that included 464 women, all younger than 40 who had given birth in the past year and had not been infected with CMV. Half were given the vaccine, and the other half were injected with a placebo. Three doses were given: at the start of the study, a month later, and again at six months.

In the first year, 49 infections with CMV occurred, the study reported. In the placebo group, 31 women were infected with CMV, compared with 18 who had been given the vaccine.

Using a statistical model, the researchers estimated that women given the vaccine would be half as likely to develop a CMV infection over a 42-month period as those given a placebo.

Dr. Navid Mootabar, director of gynecology surgery and associate chief of obstetrics and gynecology at Northern Westchester Hospital in Mt. Kisco, N.Y., described the study as "very promising."

"If we can reduce the risk of a pregnant woman acquiring CMV, then we will reduce the many neurologic and congenital risks than CMV poses to a growing fetus," he said. "However, further larger studies will be needed to ensure the safety and efficacy of the vaccine before we should recommend it to all women."

Most of the funding for the study came from the U.S. National Institutes of Health, Pass said. Sanofi Pasteur, which makes the vaccine, also helped fund the study and provided the vaccine.

Pass said that he was not aware of specific plans to conduct a phase 3 trial. But he said that, given the results, he expects the pharmaceutical company to move forward with development of the vaccine.

More information

The U.S. Centers for Disease Control and Prevention has more on CMV infections.



SOURCES: Robert Pass, M.D., professor of pediatrics, University of Alabama at Birmingham School of Medicine and Children's Hospital of Alabama; Navid Mootabar, M.D., director, gynecology surgery, and associate chief, obstetrics and gynecology, Northern Westchester Hospital, Mt. Kisco, N.Y.; March 19, 2009, New England Journal of Medicine


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Smart Phones to be used by assisTek to Collect Patient-Reported Outcomes in a Large Multinational Clinical Trial
2. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
3. Convection Cooled 150-Watt Open Frame Power Supply Meets Medical and Industrial Safety Standards
4. Patient Placement Systems Announces Free 30-Day Trial Program for Referral Management System
5. QLT announces completion of Phase Ia safety trial of its synthetic retinoid product
6. Clinical Trial Fraud Exposed by Coast IRB
7. M2S Announces New Addition to Electronic Image Management Offering for Clinical Trials
8. Surface Logix Raises $20 Million in Financing and Starts Phase 2b Clinical Trial of SLx-4090 in Dyslipidemia and Diabetes
9. Clinical trials review finds only exercise to prevent low-back problems
10. High Court Ruling Against Preemption Hurts Patients, Helps Trial Lawyers
11. Clinical trial finds microbicide promising as HIV prevention method for women
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Trial Vaccine May Protect Against Serious Viral Infection
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. Josh ... Mesa, and Chandler, Arizona. , Dr. Olson says the decision to support ...
(Date:6/24/2016)... New York (PRWEB) , ... June 24, 2016 , ... ... marijuana patients optimize the ingestion of their medication by matching users with high quality ... users to compare pieces with no commitment. , Inhale was founded by two brothers, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology: